STOCK TITAN
  1. Home
  2. News
  3. KPTI

Karyopharm Therapeutics Inc. - KPTI STOCK NEWS

Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies. The company specializes in the discovery, development, and commercialization of drugs targeting nuclear export proteins for the treatment of cancer and other significant diseases. Its flagship product, XPOVIO® (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor and is approved in the U.S. for multiple oncology indications. These include combination therapies with Velcade® (bortezomib) and dexamethasone for multiple myeloma, as well as treatments for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Recent achievements highlight the company's commitment to advancing its late-stage clinical pipeline. Notably, Karyopharm has been at the forefront in evaluating selinexor's efficacy in combination therapies for multiple myeloma, endometrial cancer, and myelofibrosis. The company recently reported long-term follow-up data from a Phase 1/3 study on selinexor in combination with ruxolitinib in myelofibrosis patients, showing promising results in spleen volume and symptom reduction.

Financially, Karyopharm reported total revenue of $33.7 million for Q4 2023, with a full-year revenue of $146.0 million. Despite a competitive market, the company managed to maintain steady growth and focused resources on its high-potential pipeline. With a cash position of $192.4 million as of December 31, 2023, Karyopharm is well-positioned to continue its innovative research and development efforts.

Karyopharm's collaborations with global partners, including Antengene, Menarini, Neopharm, and FORUS, have extended the reach of XPOVIO to various international markets such as Europe, China, South Korea, and Israel. This international expansion underscores the global demand for innovative cancer therapies.

For more information, please visit www.karyopharm.com.

News

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Karyopharm Therapeutics Inc. granted 10,250 restricted stock units to two new employees as part of its 2022 Inducement Stock Incentive Plan. Each RSU award will vest over three years, with specific conditions for accelerated vesting in case of a change in control event. The grants aim to attract and retain talent crucial for the company's growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.55%
Tags
none
-
News

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Rhea-AI Summary
Karyopharm Therapeutics Inc. reports total revenue of $146 million for 2023, with U.S. XPOVIO® net product revenue at $112 million. The company expects top-line data readouts from pivotal Phase 3 trials in 2025. Full-year 2024 revenue guidance is set at $140-160 million, including U.S. XPOVIO net product revenue guidance of $100-120 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.78%
Tags
earnings
-
News

Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

Rhea-AI Summary
Karyopharm Therapeutics Inc. (KPTI) will report its fourth quarter and full year 2023 financial results on February 29, 2024. The management team will host a conference call to discuss the results and company updates. Investors can access the call via dial-in or webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.61%
Tags
conferences earnings
News

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Karyopharm Therapeutics Inc. has granted 26,850 restricted stock units to seven newly-hired employees as part of its 2022 Inducement Stock Incentive Plan. The RSU awards will vest over three years, and each award is subject to the employee's continued service with the company. Additionally, the awards will be immediately exercisable in full in the event of a 'change in control event' and certain termination conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.56%
Tags
none
-
News

Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives

Rhea-AI Summary
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) expects top-line data readouts in 2H 2024 and 2025 from three pivotal Phase 3 studies evaluating Selinexor in Multiple Myeloma, Endometrial Cancer, and Myelofibrosis. Preliminary unaudited full year 2023 total revenue and U.S. XPOVIO (selinexor) net product revenue are expected to be approximately $146 million and $112 million, respectively. The company's cash runway is expected to extend into late 2025, supporting multiple potentially value-generating milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.92%
Tags
none
-
News

Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced that its senior management team will participate in the 42nd Annual J.P. Morgan Healthcare Conference for a podium presentation and a question-and-answer breakout session. The live webcast of the presentation can be accessed on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.55%
Tags
conferences
News

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) grants 42,000 restricted stock units (RSUs) to a newly-hired employee. The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting is subject to the employee's continued service. Additionally, the RSU award will be immediately exercisable in full if a 'change in control event' occurs and the employee's employment is terminated for 'good reason' or terminated without 'cause' by Karyopharm.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.55%
Tags
none
-
News

Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)

Rhea-AI Summary
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced long-term follow-up data from the Phase 1 study of Selinexor in combination with Ruxolitinib in treatment-naïve Myelofibrosis, suggesting disease modification and reinforcing the potential for this combination to become a novel, first-line treatment for JAKi-Naïve patients with MF.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.53%
Tags
clinical trial
-
News

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) granted 15,700 restricted stock units (RSUs) to three newly-hired employees as part of the Company's 2022 Inducement Stock Incentive Plan. The RSU awards will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting is subject to the employee's continued service, and the RSU award will be immediately exercisable in full in the event of a 'change in control event' and certain termination conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.62%
Tags
none
News

Karyopharm to Participate at Upcoming Investor Conferences

Rhea-AI Summary
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announces senior management participation in investor conferences in November, including Jefferies 2023 London Healthcare Conference and Piper Sandler 35th Annual Healthcare Conference. Live webcasts and slides available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.6%
Tags
conferences

FAQ

What is the current stock price of Karyopharm Therapeutics (KPTI)?

The current stock price of Karyopharm Therapeutics (KPTI) is $0.635 as of December 20, 2024.

What is the market cap of Karyopharm Therapeutics (KPTI)?

The market cap of Karyopharm Therapeutics (KPTI) is approximately 82.5M.

What is Karyopharm Therapeutics' main focus?

Karyopharm Therapeutics specializes in the discovery, development, and commercialization of drugs targeting nuclear export proteins for the treatment of cancer and other major diseases.

What is XPOVIO® (selinexor)?

XPOVIO® is a first-in-class, oral exportin 1 (XPO1) inhibitor approved for the treatment of multiple oncology indications, including multiple myeloma and diffuse large B-cell lymphoma (DLBCL).

What recent achievements has Karyopharm reported?

Karyopharm recently announced promising long-term follow-up data from a Phase 1/3 study on selinexor in combination with ruxolitinib for myelofibrosis. The company also reported strong financial performance with total revenue of $146.0 million for the year 2023.

Who are Karyopharm's global partners?

Karyopharm has partnered with Antengene, Menarini, Neopharm, and FORUS to market XPOVIO in international markets, including Europe, China, South Korea, and Israel.

What are Karyopharm's financial highlights?

For Q4 2023, Karyopharm reported total revenue of $33.7 million and a full-year revenue of $146.0 million. The company had a cash position of $192.4 million as of December 31, 2023.

What are the key indications for XPOVIO?

XPOVIO is approved for use in combination with Velcade and dexamethasone for multiple myeloma, in combination with dexamethasone for heavily pre-treated multiple myeloma, and as a monotherapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

What is the significance of Karyopharm's research on nuclear export proteins?

Karyopharm's research targets nuclear export dysregulation, a fundamental mechanism of oncogenesis, aiming to develop therapies that inhibit this process and treat various cancers effectively.

How does Karyopharm support clinical trials and research?

Karyopharm is engaged in several mid- and late-stage clinical trials across multiple high unmet need cancer indications, including endometrial cancer and myelofibrosis. The company also collaborates with global partners and research institutions to advance its pipeline.

What are the safety considerations for XPOVIO?

Common treatment-emergent adverse events for XPOVIO include nausea, vomiting, diarrhea, and neutropenia. Patients are advised not to breastfeed during treatment. Full prescribing information is available on www.XPOVIO.com.

How can I get more information about Karyopharm's products or clinical trials?

For more information, you can contact Karyopharm's Medical Information department at +1 (888) 209-9326 or via email at medicalinformation@karyopharm.com.

Stock KPTI logo
Karyopharm Therapeutics Inc.

Nasdaq:KPTI

KPTI Rankings

#4544 Ranked by Market Cap
N/A Ranked by Dividends

KPTI Stock Data

82.52M
117.36M
6.15%
50%
15.11%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEWTON